166 related articles for article (PubMed ID: 34355602)
21. Comparison of cytoreductive partial versus radical nephrectomy in metastatic renal cell carcinoma: To be on the horns of a dilemma.
Shemshaki H; Al-Mamari SA; Al-Hooti Q; Geelani IA; Al Salmi I; Narayana Kurukkal S; Kumar S; Al Julandani A; Sadeghzadeh S
Urologia; 2022 May; 89(2):160-166. PubMed ID: 35422178
[TBL] [Abstract][Full Text] [Related]
22. Cytoreductive radical prostatectomy versus no local treatment in patients with metastatic prostate cancer.
González-Browne C; Díaz J; Pinto I; Sandoval C; Vidal Á; Altamirano-Villarroel J
Medwave; 2023 May; 23(4):. PubMed ID: 37233030
[TBL] [Abstract][Full Text] [Related]
23. Local Therapeutics for the Treatment of Oligo Metastatic Prostate Cancer.
Jalfon MJ; Sakhalkar OV; Lokeshwar SD; Marks VA; Choksi AU; Klaassen Z; Leapman MS; Kim IY
Curr Urol Rep; 2023 Oct; 24(10):455-461. PubMed ID: 37369828
[TBL] [Abstract][Full Text] [Related]
24. Role of surgery in oligometastatic prostate cancer.
Jenjitranant P; Touijer KA
Prostate Int; 2019 Dec; 7(4):125-130. PubMed ID: 31970136
[TBL] [Abstract][Full Text] [Related]
25. Emerging role of cytoreductive prostatectomy in patients with metastatic disease.
Jaber Y; Reichard CA; Chapin BF
Transl Androl Urol; 2018 Sep; 7(Suppl 4):S505-S513. PubMed ID: 30363448
[TBL] [Abstract][Full Text] [Related]
26. The cytoreductive radical prostatectomy in metastatic prostate cancer.
Vladimír Š; Zuzana S; Hana Š
Klin Onkol; 2022; 35(1):55-62. PubMed ID: 35236082
[TBL] [Abstract][Full Text] [Related]
27. Cytoreductive Radical Prostatectomy for Metastatic Hormone-sensitive Prostate Cancer-Evidence from Recent Prospective Reports.
Rajwa P; Zattoni F; Maggi M; Marra G; Kroyer P; Shariat SF; Briganti A; Montorsi F; Heidegger I; Gandaglia G;
Eur Urol Focus; 2023 Jul; 9(4):637-641. PubMed ID: 36697321
[TBL] [Abstract][Full Text] [Related]
28. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.
Preisser F; Chun FKH; Pompe RS; Heinze A; Salomon G; Graefen M; Huland H; Tilki D
Eur Urol; 2019 Jul; 76(1):106-114. PubMed ID: 30772034
[TBL] [Abstract][Full Text] [Related]
29. Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer.
Preisser F; Mazzone E; Nazzani S; Bandini M; Tian Z; Marchioni M; Steuber T; Saad F; Montorsi F; Shariat SF; Huland H; Graefen M; Tilki D; Karakiewicz PI
Eur Urol; 2018 Dec; 74(6):693-696. PubMed ID: 30037529
[TBL] [Abstract][Full Text] [Related]
30. Long-term cancer control outcomes of robot-assisted radical prostatectomy for prostate cancer treatment: a meta-analysis.
Wang L; Wang B; Ai Q; Zhang Y; Lv X; Li H; Ma X; Zhang X
Int Urol Nephrol; 2017 Jun; 49(6):995-1005. PubMed ID: 28238148
[TBL] [Abstract][Full Text] [Related]
31. Cytoreductive prostatectomy may improve oncological outcomes in patients with oligometastatic prostate cancer: An updated systematic review and meta-analysis.
Chung DY; Kang DH; Jung HD; Lee JY; Kim DK; Ha JS; Jeon J; Cho KS
Investig Clin Urol; 2023 May; 64(3):242-254. PubMed ID: 37341004
[TBL] [Abstract][Full Text] [Related]
32. Comparison of Open Versus Robotically Assisted Cytoreductive Radical Prostatectomy for Metastatic Prostate Cancer.
Preisser F; Nazzani S; Mazzone E; Marchioni M; Bandini M; Tian Z; Haese A; Saad F; Zorn K; Montorsi F; Shariat SF; Graefen M; Tilki D; Karakiewicz PI
Clin Genitourin Cancer; 2019 Oct; 17(5):e939-e945. PubMed ID: 31375352
[TBL] [Abstract][Full Text] [Related]
33. Risk of complications and urinary incontinence following cytoreductive prostatectomy: a multi-institutional study.
Kim DK; Parihar JS; Kwon YS; Kim S; Shinder B; Lee N; Farber N; Ahlering T; Skarecky D; Yuh B; Ruel N; Kim WJ; Rha KH; Kim IY
Asian J Androl; 2018; 20(1):9-14. PubMed ID: 28440262
[TBL] [Abstract][Full Text] [Related]
34. Local treatment Associated With Prognosis among Men With Metastatic Prostate Cancer: A SEER-Based Study.
Zhou J; Cao Y; Chen H; Wu Y; Ding J; Qi J
Clin Genitourin Cancer; 2023 Jun; 21(3):e204-e215. PubMed ID: 36858922
[TBL] [Abstract][Full Text] [Related]
35. The prognosis benefits of adjuvant versus salvage radiotherapy for patients after radical prostatectomy with adverse pathological features: a systematic review and meta-analysis.
Tao R; Dai J; Bai Y; Yang J; Sun G; Zhang X; Zhao J; Zeng H; Shen P
Radiat Oncol; 2019 Nov; 14(1):197. PubMed ID: 31706339
[TBL] [Abstract][Full Text] [Related]
36. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
Culp SH; Schellhammer PF; Williams MB
Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
[TBL] [Abstract][Full Text] [Related]
37. [Radical cancer surgery of renal cell and prostate carcinoma with hematogenous metastasis: benefits].
Heidenreich A; Pfister D; Porres D
Urologe A; 2014 Jun; 53(6):823-31. PubMed ID: 24824471
[TBL] [Abstract][Full Text] [Related]
38. Comparison of Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy Strategies as Primary Treatment for High-risk Localized Prostate Cancer: A Systematic Review and Meta-analysis.
Greenberger BA; Zaorsky NG; Den RB
Eur Urol Focus; 2020 Mar; 6(2):404-418. PubMed ID: 31813810
[TBL] [Abstract][Full Text] [Related]
39. Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives.
Bayne CE; Williams SB; Cooperberg MR; Gleave ME; Graefen M; Montorsi F; Novara G; Smaldone MC; Sooriakumaran P; Wiklund PN; Chapin BF
Eur Urol; 2016 May; 69(5):775-87. PubMed ID: 26003223
[TBL] [Abstract][Full Text] [Related]
40. Local Therapy Improves Survival in Metastatic Prostate Cancer.
Leyh-Bannurah SR; Gazdovich S; Budäus L; Zaffuto E; Briganti A; Abdollah F; Montorsi F; Schiffmann J; Menon M; Shariat SF; Fisch M; Chun F; Steuber T; Huland H; Graefen M; Karakiewicz PI
Eur Urol; 2017 Jul; 72(1):118-124. PubMed ID: 28385454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
